Last edition
News about "Astellas"
Lupin Resolves Mirabegron Patent Dispute with Astellas in USD 90 Million Settlement
Lupin Limited has reached a USD 90 million settlement to resolve a patent dispute with Japan-based Astellas Pharma concerning Lupin’s generic version of mirabegron, a treatment for overactive bladder. The agreement concludes ongoing litigation in the United States and provides commercial clarity around Lupin’s continued participation in the market.
Astellas | 11/02/2026 | By Darshana
Astellas Gets EU Approval for VYLOY in Combination with Chemotherapy
Astellas Pharma Inc. has announced that the European Commission (EC) has approved VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy.
Astellas | 23/09/2024 | By Aishwarya | 656
Sandoz Acquires Astellas' Antifungal Agent Mycamine
The company stated "Through this acquisition of the leading global echinocandin, one of three major antifungal classes, Sandoz significantly reinforces its global hospital offering and leading anti-infectives portfolio.
Astellas | 29/08/2023 | By Manvi | 610
Verizon Business selected to transform Astellas Pharma's global network infra
Digital transformation is seen as critical enabler in delivering improved patient outcomes and future growth
Astellas | 10/08/2022 | By Sudeep Soparkar | 1323
Astellas plans to open biotech campus in South San Francisco
Astellas will invest approximately $70 million to create the new state-of-the-art facility, which will provide lab and co-working spaces to accommodate future growth
Astellas | 22/07/2022 | By Sudeep Soparkar | 1111
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy